It all starts with a patient

Global Liver Institute saves lives by empowering patient advocates to collaborate with policymakers, clinicians, and industry to drive the liver health field forward.

It all starts with a patient

Global Liver Institute saves lives by empowering patient advocates to collaborate with policymakers, clinicians, and industry to drive the liver health field forward.

It all starts with a patient

Global Liver Institute saves lives by empowering patient advocates to collaborate with policymakers, clinicians, and industry to drive the liver health field forward.

It all starts with a patient

Global Liver Institute saves lives by empowering patient advocates to collaborate with policymakers, clinicians, and industry to drive the liver health field forward.

GLILogo Xl

It all starts with a patient

Global Liver Institute saves lives by empowering patient advocates to collaborate with policymakers, clinicians, and industry to drive the liver health field forward.

Patient Testimonials

How we’re making a difference.

Katelin H

Dr. Katelin H.

“There is nothing more powerful than sharing your story with others, whether with your own family or with the whole country. You’d be surprised how much impact simple actions can have.”

Karen Hoyt

Karen Hoyt

“Connecting to others with liver disease is so crucial. It is easy to get caught in a cycle of malnutrition, fatigue, isolation, depression, pain, and on it goes. By reaching out to others, and their caregivers, I aspire to inspire connections from around the globe.”

Elena P

Elena Covarrubias

“As a professional I’ve worked with hundred of people with NASH and detected some others. I know this disease is not known enough by people and by health professionals, even physicians. My duty is to identify those in risk of developing NASH and NAFLD.”

About GLI

Improving the lives of individuals & families.

Global Liver Institute (GLI) is a nonprofit organization founded in the belief that liver health must take its place on the global public health agenda commensurate with the prevalence and impact of liver illness.

GLI promotes innovation, encourages collaboration, and supports the scaling of optimal approaches to help eradicate liver diseases. Operating globally, GLI is committed to solving the problems that matter to liver patients and equipping advocates to improve the lives of individuals and families impacted by liver disease.

Global Liver Home3

1.5 Billion

people around the globe are currently living with liver disease1

Global Liver Home2

1 in 4

people are estimated to already have NAFLD or NASH2

Woman Showing Liver

Less than 27%

of people with liver cancer survive five years after diagnosis, worldwide.3

Leadership in Liver Health Luncheon

Join us this year as we honor the Leadership in Liver Health Award recipients:

  • Dr. Michelle McMurry-Heath, President and CEO of Biotechnology Innovation Organization, with the Global Excellence in Health Equity Award
  • Dr. Leana S. Wen, Public Health Professor, George Washington University and Contributing Columnist, Washington Post, with the Global Excellence in Health Communications Award.
Leadership In Liver Health Luncheon
Gli Live Logo

GLI LIVE started in March 2020, as a COVID-19 response program for liver patients. It has now evolved into a weekly educational show with tailored information for patients living with liver diseases on a variety of timely topics.

Livercentral Logo

Global Liver Institute created Liver Central to equip everyone affected by liver cancer. We know that learning, advocacy, and collaboration empowers us to create change in the exam room, in the community, and beyond. Whether you have just received a liver cancer diagnosis, you are interested in new treatment options or clinical trials, or you’re a clinician looking for current practice guidelines, Liver Central exists to help you find the answers you pursue.

Latest Updates

Liver Health Policy Update

Congress begins Fiscal Year 2025 appropriations process and the Administration approves new treatments improving the lives of liver disease patients.

After a brief weekend shutdown, Congress passed the FY 2024 appropriations bills and President Joe Biden signed the $1.2 trillion government funding package on March 23, 2024, closing the books on fiscal year (FY) 2024 appropriations.

pediatric and rare liver diseases news square

Celebrating the benefits of drug repurposing for pediatric rare liver disease patients – Pediatric & Rare Liver Diseases News

Global Liver Institute (GLI) celebrates a major breakthrough with the U.S. FDA’s approval for Mirum Pharmaceuticals’s Livmarli (maralixibat chloride) to address cholestatic pruritus in patients aged 5 and above with progressive familial intrahepatic cholestasis (PFIC).

NASH News

GLI Celebrates US Treatment for NASH as Milestone for Liver Health – NASH News

The U.S. FDA approves Madrigal Pharmaceuticals Rezdiffra™ (resmetirom) as the FIRST NASH therapeutic option in the U.S.
This breakthrough follows years of NASH patient-led multi-stakeholder advocacy and partnership with researchers in drug development.